Accenture Releases Report on What Patients Want
Accenture released a new report on product launches in the pharmaceutical industry, based on a survey of 8,000 patients in France, Germany, the UK, and the U.S., across eight therapeutic areas-immunology, cardiology, pulmonology, neurology, oncology, rheumatology, endocrinology, and eye disease. The report is designed to help pharma companies understand what will help enable them to launch new treatments successfully in a market characterized by more-complex specialty therapeutics, rising costs, and an intensified focus on value and outcomes.
Findings in the report include that brands are not major influencing factors when patients consider new pharmaceutical products; more than two-thirds (69%) of patients surveyed said the product’s benefits (i.e., treatment outcomes) are more important than the brand itself, with less than one-third (31%) citing a strong affinity to brands in a healthcare setting.
Based on survey findings, the report offers two major recommendations for pharma companies, 1) bring an outcome, not just a product, to market and 2) make it personal and precise.
View the full report here.
Reshema Kemps-Polanco: Taking Risks for Greater Reward
May 14th 2025Reshema Kemps-Polanco, executive VP and chief commercial officer, Novartis US, and the 2025 Healthcare Businesswomen’s Association Woman of the Year, uses the lessons she learned from her family to bring out the best in her teams.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Novo Nordisk’s Sogroya Demonstrates Efficacy in Children with Growth Disorders
May 14th 2025Results from the Phase III REAL8 basket study found that once-weekly Sogroya was effective in children with growth disorders, including those born small for gestational age, with Noonan syndrome, or idiopathic short stature.
